Home LiteratureArticle Details
PMID: 2073317 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Transplantation of discordant xenografts: a review of progress.

Immunology today ·Vol. 11 ·No. 12 ·1990-12-00 ·Pages 450-6; discussion 456-7

Platt JL, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, Najarian JS, Bach FH

Abstract

Hyperacute rejection, apparently initiated by natural antibodies and complement, has been viewed as an absolute barrier to the xenotransplantation of vascularized grafts between different species. Until recently, little was known about the molecular and physiological basis for this barrier nor was there evidence that the barrier might be more than transiently breached. In this paper Jeffrey Platt, Fritz Bach and colleagues describe a model of hyperacute rejection and propose that, if hyperacute rejection can be averted for a period after transplantation, prolonged xenograft survival will be possible.

MeSH Terms
Animals Chondroitin Sulfate Proteoglycans/metabolism Complement System Proteins/immunology Endothelium/physiology Graft Rejection Graft Survival Heparan Sulfate Proteoglycans Heparitin Sulfate/metabolism Humans Immunity, Cellular Transplantation, Heterologous
Chemicals
Chondroitin Sulfate Proteoglycans Heparan Sulfate Proteoglycans Complement System Proteins Heparitin Sulfate
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Platt J L
Dept of Pediatrics, University of Minnesota, Minneapolis 55455.
Vercellotti G M
Dalmasso A P
Matas A J
Bolman R M
Najarian J S
Bach F H
Article Info
Journal
Immunology today
Abbr.
Immunol Today
ISSN
0167-5699
Published
1990-12-00
Pages
450-6; discussion 456-7
Language
English
Region
England
NLM ID
8008346
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com